RT Journal Article
SR Electronic
T1 Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4291
OP 4297
DO 10.21873/anticanres.14431
VO 40
IS 8
A1 SHIMURA, YUSUKE
A1 SUGA, YUKIO
A1 ITAI, SHINGO
A1 IWAMOTO, HIROAKI
A1 TAKEZAWA, YUTA
A1 YAEGASHI, HIROSHI
A1 IZUMI, KOUJI
A1 SHIMADA, TSUTOMU
A1 SAI, YOSHIMICHI
A1 MATSUSHITA, RYO
A1 MIZOKAMI, ATSUSHI
YR 2020
UL http://ar.iiarjournals.org/content/40/8/4291.abstract
AB Background: The tolerability of 2-weekly docetaxel at 25-35 mg/m2 for castration-resistant prostate cancer (CRPC) has not been fully evaluated. The aim of this study was to evaluate its tolerability compared to 3-weekly docetaxel at 60-75 mg/m2 in patients with CRPC. Patients and Methods: In this retrospective study, data were compared with respect to efficacy and safety between 2-weekly and 3-weekly docetaxel regimens in patients with CRPC. Results: Time to treatment failure and prostate-specific antigen (PSA) response rate did not differ significantly between the two regimens. Compared to 3-weekly administration, incidence of severe leukopenia and febrile neutropenia was significantly lower (p<0.05), and relative dose intensity was significantly higher (p<0.05) for the 2-weekly schedule. Docetaxel dosage and PSA response were identified as independent risk factors for severe leukopenia. Conclusion: Two-weekly treatment seems better tolerated than three-weekly treatment in Japanese patients with CRPC.